DGDavid Guez

David Guez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Guez has a total of 707 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The application of point source electroporation and chemotherapy for the treatment of glioma: a randomized controlled rat study

    by Shirley Sharabi, David Guez, Dianne Daniels, Itzik Cooper, Dana Atrakchi, Sigal Liraz-Zaltsman, David Last, Yael Mardor

    The prognosis of Glioblastoma Multiforme patients is poor despite aggressive therapy. Reasons include poor chemotherapy penetration across the blood-brain barrier and tumor infiltration into surrounding tissues. Here we studied the effects of combined point-source electroporation (EP) and systemic chemotherapy in glioma-bearing rats. 128 rats were studied. Treatment groups were administered systemic Cisplatin/Methotrexate before EP (either 90 or 180 pulses). Control groups were treated by EP, chemotherapy, or no treatment. Tumor volumes were determined by MRI. Tumors growth rates of the EP + Methotrexate group (1.02 ± 0.77) were significantly lower (p < 0.01) than the control (5.2 ± 1.0) 1-week post treatment. No significant difference was found compared to Methotrexate (1.7 ± 0.5). Objective response rates (ORR) were 40% and 57% for the Methotrexate and EP + Methotrexate groups respectively. Tumor growth rates and ORR of the EP + Cisplatin groups (90 pulses 0.98 ± 0.2, 57%, 180 pulses 1.2 ± 0.1, 33%) were significantly smaller than the control (6.4 ± 1.0, p < 0.01, p < 0.02, 0%) and Cisplatin (3.9 ± 1.0, p < 0.04, p < 0.05, 13%) groups. No significant differences were found between the control groups. Increased survival was found in the EP + Cisplatin group, Χ2 = 7.54, p < 0.006 (Log Rank). Point-source EP with systemic chemotherapy is a rapid, minimal-invasive treatment that was found to induce significant antineoplastic effects in a rat glioma model.


  • Magnetic resonance imaging for prenatal estimation of birthweight in pregnancy: review of available data, techniques, and future perspectives

    by Caroline Kadji, Mieke M. Cannie, Serena Resta, David Guez, Fouad Abi-Khalil, Riccardo De Angelis, Jacques C. Jani


  • Open Access

    Radiation-induced vascular malformations in the brain, mimicking tumor in MRI-based treatment response assessment maps (TRAMs)

    by David Guez, David Last, Dianne Daniels, Shirley Sharabi, Dvora Nass, Ouzi Nissim, Roberto Spiegelmann, Galia Tzarfaty, Chen Hoffmann, Alisa Talianski, et al.


  • Non-thermal focused ultrasound induced reversible reduction of essential tremor in a rat model

    by Shirley Sharabi, Dianne Daniels, David Last, David Guez, Zion Zivli, David Castel, Yoav Levy, Alexander Volovick, Javier Grinfeld, Itay Rachmilevich, et al.


  • NIMG-35. TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs) SENSITIVITY TO TUMOR/TREATMENT-EFFECTS AS A FUNCTION OF DATA ACQUISITION PARAMETERS

    by David Guez, Leor Zach, Dianne Daniels, Shirley Sharabi, Ouzi Nissim, Roberto Spiegelmann, Arielle Tylim, Alisa Taliansky, Yigal Shoshan, Deborah Blumenthal, et al.

    TRAMs calculated from delayed-contrast MRI enable reliable (sensitivity/specificity>70%) differentiation between tumor (blue in the TRAMs) and non-tumoral tissues (red). The TRAMs are calculated by subtracting 3D T1-MRIs acquired 5min (early time point) post-contrast injection from those acquired 60-105min (late point) later. Here we studied the sensitivity to tumor/treatment-effects as a function of the early T1-MRI acquisition time. 7 patients with high grade glioma and 6 with brain metastases were scanned by the standard TRAMs protocol with the addition of a rapid 3D T1-MRI sequence (20 sec) acquired 2, 5, 12, 17, 20, 24 and 70 min post-contrast. Rapid-TRAMs were calculated using the rapid T1-MRIs, where the late time point was fixed at 70 min and the early time point changed from 2 to 24 min post-contrast. Enhancing volumes were determined on the T1-MRIs and copied to the TRAMs. Blue/tumor and red/treatment-effects volumes were calculated within the enhancing regions. The blue/tumor volumes, calculated from the rapid-TRAMs, increased by a factor of 4.4 ± 2.6 when moving the early time point from 2min to 15.7 ± 2.2min, where they plateaued. The increase between 5min (standard) and 15.7min was by 1.5 ± 0.3. In contrast, when moving from 2 min to 15.7min the red/treatment-effects volumes decreased by 0.7 ± 0.2, and by 0.8 ± 0.1 when moving from 5min. CONCLUSIONS: The TRAMs were shown to provide reliable differentiation between tumor/treatment-effects. The early time point is fixed at 5min post-contrast. Using shorter delays may significantly decrease the sensitivity to tumor. Still, increasing the delay to 15min may increase the sensitivity to tumor. This over-estimation of the tumor volume may be explained by the tumor vasculature clearing contrast diffusing into further brain regions surrounding the tumor. An additional 3D-T1 acquired at 15min may be applied for calculating additional TRAMs with higher sensitivity to tumor, for depicting small tumor regions.


  • Focused Ultrasound-Induced Suppression of Auditory Evoked Potentials in Vivo

    by Dianne Daniels, Shirley Sharabi, David Last, David Guez, Sharona Salomon, Zion Zivli, David Castel, Alex Volovick, Javier Grinfeld, Itay Rachmilevich, et al.


  • Open Access

    NIMG-52. RADIATION-INDUCED VASCULAR MALFORMATIONS MIMICKING TUMOR IN MRI-BASED TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs)

    by Leor Zach, David Guez, David Last, Dianne Daniels, Shirley Sharabi, Dvora Nass, Ouzi Nissim, Roberto Spiegelmann, Galia Tsarfaty, Chen Hoffmann, et al.

    We have recently presented MRI-based TRAMs enabling efficient separation between tumor (contrast clearance >1hour post injection, blue) and treatment-effects (TEs, contrast accumulation, red), validated histologically in 51 resected patients reaching 92%/100% PPV/sensitivity to morphologically active tumor. This high selectivity stems from the ability of viable vessels in blue/tumor regions to efficiently clear contrast by 1hour, while damaged lumens in red/TEs regions are unable to, resulting in contrast accumulation. ~400 adult patients have been recruited to our studies in Israel since 2010. As the TRAMs cannot differentiate blood vessels from active tumor (both appearing blue), we studied whether radiation-induced cavernoma-like vascular malformations (RICMs) may mimic tumors in the TRAMs. Cases in which the pre-surgical TRAMs were found false-positive for tumor were re-reviewed. For comparison, 2 patients with newly diagnosed cavernomas and 4 with treated AVMs were scanned by the TRAMs. One AVM underwent TRAMs-guided biopsies. Four cases of false-positive TRAMs showing RICMs in histology were found between 2010-2017: GBM post Stupp followed by Avastin+Rindopepimut, breast and NSCLC metastases post SRS, and resected NSCLC post SRS to the surgery site. The pre-surgical TRAMs of the GBM and post-resection NSCLC showed 2-3mm blue masses within larger thin blue rims. The metastases depicted thin blue rims surrounding red regions. Histology revealed clusters of connective tissue with multiple vessel-channels in all 4 cases, consistent with RICMs at various stages of tissue re-organization. The treated AVMs TRAMs showed mixed blue/red regions. Biopsies taken from blue regions revealed large vessels, some showing re-organization; red regions showed TEs. The cavernomas were depicted blue in the TRAMs. The TRAMs reliability in differentiating tumor from TEs has been validated histologically reaching PPV=92%. The presented findings suggest that RICMs, as other vascular-malformations, may mimic tumor (blue) in the TRAMs, thus explaining false-positive cases.

  • Incorporation of relative cerebral blood flow into CT perfusion maps reduces false ’at risk' penumbra

    by Shlomi Peretz, David Orion, David Last, Yael Mardor, Yotam Kimmel, Shelly Yehezkely, Eyal Lotan, Ze’eV Itsekson-Hayosh, Sylvia Koton, David Guez, et al.

    Purpose The region defined as ‘at risk’ penumbra by current CT perfusion (CTP) maps is largely overestimated. We aimed to quantitate the portion of true ‘at risk’ tissue within CTP penumbra and to determine the parameter and threshold that would optimally distinguish it from false ‘at risk’ tissue, that is, benign oligaemia. Methods Among acute stroke patients evaluated by multimodal CT (NCCT/CTA/CTP) we identified those that had not undergone endovascular/thrombolytic treatment and had follow-up NCCT. Maps of absolute and relative CBF, CBV, MTT, TTP and Tmax as well as summary maps depicting infarcted and penumbral regions were generated using the Intellispace Portal (Philips Healthcare, Best, Netherlands). Follow-up CT was automatically co-registered to the CTP scan and the final infarct region was manually outlined. Perfusion parameters were systematically analysed – the parameter that resulted in the highest true-negative-rate (ie, proportion of benign oligaemia correctly identified) at a fixed, clinically relevant false-negative-rate (ie, proportion of ‘missed’ infarct) of 15%, was chosen as optimal. It was then re-applied to the CTP data to produce corrected perfusion maps. Results Forty seven acute stroke patients met selection criteria. Average portion of infarcted tissue within CTP penumbra was 15%±2.2%. Relative CBF at a threshold of 0.65 yielded the highest average true-negative-rate (48%), enabling reduction of the false ‘at risk’ penumbral region by ~half. Conclusions Applying a relative CBF threshold on relative MTT-based CTP maps can significantly reduce false ‘at risk’ penumbra. This step may help to avoid unnecessary endovascular interventions.


  • Liposomal temozolomide drug delivery using convection enhanced delivery

    by Mirjam M. Nordling-David, Roni Yaffe, David Guez, Hadar Meirow, David Last, Etty Grad, Sharona Salomon, Shirley Sharabi, Yael Levi-Kalisman, Gershon Golomb, et al.


  • Open Access

    International Society for Therapeutic Ultrasound Conference 2016

    by Brian Fowlkes, Pejman Ghanouni, Narendra Sanghvi, Constantin Coussios, Paul C. Lyon, Michael Gray, Christophoros Mannaris, Marie de Saint Victor, Eleanor Stride, Robin Cleveland, et al.